

Atanas Ignatov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6705280/publications.pdf>

Version: 2024-02-01

79
papers

2,069
citations

201385

27
h-index

264894

42
g-index

83
all docs

83
docs citations

83
times ranked

2704
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 803-810.	1.2	4
2	The importance of the cerebroplacental ratio for the prognosis of neonatal outcome in AGA fetuses. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 311-317.	0.8	1
3	Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2022, 164, 68-75.	0.6	12
4	BCL3 expression is strongly associated with the occurrence of breast cancer relapse under tamoxifen treatment in a retrospective cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 529-541.	1.4	7
5	Survival Advantage of Lymphadenectomy in Patients with Ovarian Cancer. <i>Cancer Investigation</i> , 2022, , 1-17.	0.6	0
6	Protective effect of pre-operative conization in patients undergoing surgical treatment for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2022, 166, 57-60.	0.6	6
7	Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 715-727.	1.1	4
8	Contralateral lymph node metastases in patients with vulvar cancer and unilateral sentinel lymph node metastases. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1520-1525.	1.3	4
9	The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. <i>Cancer Biomarkers</i> , 2021, 32, 161-173.	0.8	2
10	p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 595.e1-595.e11.	0.7	21
11	<i>STRN-ALK</i> Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1507-1513.	1.5	5
12	Minimal-invasive or open approach for surgery of early cervical cancer: the treatment center matters. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 503-510.	0.8	9
13	The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: a retrospective analysis. <i>Wspolczesna Onkologia</i> , 2021, 25, 204-212.	0.7	1
14	GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 565-571.	0.8	15
15	Glyoxalase 1 expression analysis by immunohistochemistry in breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153257.	1.0	3
16	Comparison of survival of patients with endometrial cancer undergoing sentinel node biopsy alone or systematic lymphadenectomy. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 995-1000.	0.8	9
17	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	3.0	32
18	G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: impact of GPER-1 mRNA on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3175-3188.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. <i>British Journal of Cancer</i> , 2020, 123, 33-37.	2.9	17
20	Systematic lymphadenectomy in early stage endometrial cancer. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 231-239.	0.8	6
21	Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. <i>Cancers</i> , 2020, 12, 1766.	1.7	41
22	Predicting the course of disease in recurrent vulvar cancer – A subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019, 154, 571-576.	0.6	15
23	Lymph node micrometastases and outcome of endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 475-479.	0.6	40
24	Puerperal mastitis in the past decade: results of a single institution analysis. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1637-1644.	0.8	10
25	Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1369-1376.	1.2	8
26	Loss of HER2 after HER2-targeted treatment. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 401-408.	1.1	41
27	Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact. <i>RNA Biology</i> , 2019, 16, 661-674.	1.5	8
28	G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 121-127.	1.1	34
29	Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. <i>British Journal of Cancer</i> , 2019, 120, 301-305.	2.9	27
30	Management of elderly women with cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 961-967.	1.2	25
31	Patterns of breast cancer relapse in accordance to biological subtype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1347-1355.	1.2	60
32	Laparoscopic-assisted vaginal hysterectomy versus vaginal hysterectomy for benign uterine diseases: a prospective, randomized, multicenter, double-blind trial (LAVA). <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 479-485.	0.8	8
33	Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1103-1107.	1.2	18
34	A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 381-387.	1.2	5
35	Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 337-341.	1.2	26
36	Endometrial cancer subtypes are associated with different patterns of recurrence. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2011-2017.	1.2	18

#	ARTICLE	IF	CITATIONS
37	Vaginal brachytherapy for endometrial cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1523-1530.	1.2	2
38	Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase II \pm) in borderline ovarian tumors: Correlation with clinicopathological features. Histology and Histopathology, 2018, 33, 171-179.	0.5	6
39	Endometriumkarzinom bei der alten und geriatrischen Patientin. , 2018, , 429-435.		0
40	<i>GPER</i> Promoter Methylation Controls GPER Expression in Breast Cancer Patients. Cancer Investigation, 2017, 35, 100-107.	0.6	16
41	Management of small T1a/b breast cancer by tumor subtype. Breast Cancer Research and Treatment, 2017, 163, 111-118.	1.1	25
42	Perinatal and maternal outcomes at term in low-risk pregnancies according to NICE criteria: comparison between a tertiary obstetrical hospital and midwife-attended units. Archives of Gynecology and Obstetrics, 2017, 296, 223-229.	0.8	1
43	High neuronatin (NNAT) expression is associated with poor outcome in breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 23-30.	1.4	22
44	Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases. Histochemistry and Cell Biology, 2017, 147, 625-634.	0.8	30
45	Endometrial cancer after ulipristal acetate for uterine fibroma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 219, 134.	0.5	5
46	Management of elderly women with endometrial cancer. Gynecologic Oncology, 2017, 146, 519-524.	0.6	29
47	Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer. Strahlentherapie Und Onkologie, 2017, 193, 1048-1055.	1.0	12
48	Endometriumkarzinom bei der alten und geriatrischen Patientin. , 2017, , 1-7.		0
49	Hormone receptor status does not alter the effect of trastuzumab in breast cancer. Endocrine-Related Cancer, 2016, 23, 349-355.	1.6	6
50	Ultrasound-Guided Versus Wire-Guided Breast-Conserving Surgery for Nonpalpable Breast Cancer. Clinical Breast Cancer, 2016, 16, e1-e6.	1.1	23
51	Tumor characteristics and therapy of elderly patients with breast cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1109-1116.	1.2	29
52	Peritoneal closure during laparoscopic supracervical hysterectomy. Archives of Gynecology and Obstetrics, 2016, 294, 785-789.	0.8	2
53	Role of tumour-free margin distance for loco-regional control in vulvar cancerâ€”a subset analysis of the Arbeitsgemeinschaft GynÄkologische Onkologie CaRE-1 multicenter study. European Journal of Cancer, 2016, 69, 180-188.	1.3	64
54	Survival advantage of lymphadenectomy in endometrial cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1051-1060.	1.2	41

#	ARTICLE	IF	CITATIONS
55	Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 1272-1280.	1.1	14
56	Should the hyperechogenic halo around malignant breast lesions be included in the measurement of tumor size?. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 311-317.	1.1	7
57	Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 489-495.	1.2	37
58	Clinical Implications of Growth Pattern and Extension of Tumor-Associated Intraductal Carcinoma of the Breast. <i>Clinical Breast Cancer</i> , 2015, 15, 227-233.	1.1	2
59	Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 357-364.	1.1	22
60	Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 725-733.	1.6	80
61	GPER functions as a tumor suppressor in triple-negative breast cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 713-723.	1.2	56
62	Ultrasonography-Guided Breast-Conserving Surgery Is Superior to Palpation-Guided Surgery for Palpable Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 40-45.	1.1	25
63	GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 663-671.	1.2	43
64	BRCA1 promoter methylation is a marker of better response to platinum taxane-based therapy in sporadic epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1457-1463.	1.2	22
65	Accuracy of ultrasound-guided breast-conserving surgery in the determination of adequate surgical margins. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 129-136.	1.1	35
66	GPER-1 acts as a tumor suppressor in ovarian cancer. <i>Journal of Ovarian Research</i> , 2013, 6, 51.	1.3	80
67	GPER-1 Expression Decreases During Breast Cancer Tumorigenesis. <i>Cancer Investigation</i> , 2013, 31, 309-315.	0.6	41
68	BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 205-212.	1.1	31
69	Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 465-470.	1.1	131
70	G protein-coupled estrogen receptor (GPER) expression in endometrial adenocarcinoma and effect of agonist G-1 on growth of endometrial adenocarcinoma cell lines. <i>Steroids</i> , 2013, 78, 1087-1091.	0.8	27
71	G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 457-466.	1.1	144
72	Comparative Study of Surgical Margins and Cosmetic Outcome in Lumpectomy versus Segmental Resection in Breast Cancer. <i>European Surgical Research</i> , 2011, 47, 231-239.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Research and Treatment, 2010, 123, 87-96.	1.1	138
74	Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. American Journal of Obstetrics and Gynecology, 2010, 203, 595.e9-595.e16.	0.7	33
75	APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Science, 2010, 101, 321-327.	1.7	42
76	P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecologic Oncology, 2008, 111, 365-371.	0.6	35
77	Reproductive Outcome of Women with Rare Müllerian Anomaly: Report of 2 Cases. Journal of Minimally Invasive Gynecology, 2008, 15, 502-504.	0.3	6
78	RANTES stimulates Ca ²⁺ mobilization and inositol trisphosphate (IP ₃) formation in cells transfected with G protein-coupled receptor 75. British Journal of Pharmacology, 2006, 149, 490-497.	2.7	89
79	Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca ²⁺ release by activating the sphingosine-kinase pathway. Biochemical and Biophysical Research Communications, 2003, 311, 329-336.	1.0	57